Holen Sie sich die Stockscreener-App
2.50
11.11%
0.25
Vorhandelsmarkt:
2.42
-0.08
-3.20%
Schlusskurs vom Vortag:
$2.25
Offen:
$2.25
24-Stunden-Volumen:
1.03M
Relative Volume:
1.70
Marktkapitalisierung:
$367.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-11.13
EPS:
-0.2247
Netto-Cashflow:
-
1W Leistung:
+47.06%
1M Leistung:
+43.68%
6M Leistung:
+34.41%
1J Leistung:
+17.92%
1-Tages-Spanne:
$2.25
$2.63
1-Wochen-Bereich:
$1.75
$3.5299
52-Wochen-Spanne:
$1.32
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Firmenname
Immutep Limited Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IMMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
2.50 | 331.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-17 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-07-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-09-28 | Eingeleitet | B. Riley FBR | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Immutep Limited Adr Aktie (IMMP) Neueste Nachrichten
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - Setenews
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - Setenews
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Reversal indicators forming on Immutep Limited Depositary Receipt stockMarket Activity Summary & Safe Entry Point Alerts - newser.com
What momentum shifts mean for Immutep Limited Depositary Receipt2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewswire Inc.
Immutep Limited Depositary Receipt Stock Lags Behind Sector BenchmarksMarket Performance Report & Weekly Setup with High ROI Potential - beatles.ru
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
12 Best Australian Stocks to Buy Right Now - Insider Monkey
Immutep Gains FDA Support for Cancer Therapy Development - TipRanks
Is Immutep Limited Depositary Receipt a good long term investmentFree Stock Market Return Analysis - PrintWeekIndia
Immutep Limited Depositary Receipt Stock Analysis and ForecastExceptional gains - jammulinksnews.com
Millennium Management LLC Sells 19,242 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Jane Street Group LLC Has $98,000 Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference - TipRanks
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep stock soars on promising trial results - Investing.com
Immutep Advances Cancer Trials with Promising Developments - TipRanks
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now? - AInvest
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Immutep appoints research institute to conduct first-in-human study of IMP761 - Biotech Dispatch
symbol__ Stock Quote Price and Forecast - CNN
Immutep LimitedADR (IMMP) Price Target Increased by 5.10% to 2.59 - Nasdaq
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - targetedonc.com
72 Biggest Movers From Friday - Benzinga
Immutep Limited (ASX: IMM) - The Motley Fool Australia
Immutep Limited Share Price ADR each Representing 10 Shares - Hargreaves Lansdown
Immutep valuation increased 16% to $510 million by Edison Investment Research - Proactive financial news
Technical Analysis of Immutep Ltd Sponsored ADR (NASDAQ:IMMP) - TradingView
IMM Stock Price and Chart — ASX:IMM - TradingView
IMMP - Finviz
IMMP Stock Price | Immutep Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat
IMMP Stock Price and Chart — NASDAQ:IMMP - TradingView
Zai Lab Limited (ZLAB) stock price, news, quote and history - Yahoo Finance UK
Prima BioMed Share Price | NASDAQ IMMP Stock - Investing.com Australia
Prima BioMed Stock Price Today | NASDAQ: IMMP Live - Investing.com
Immutep Ltd Share Price | ASX IMM Stock - Investing.com Australia
Finanzdaten der Immutep Limited Adr-Aktie (IMMP)
Es liegen keine Finanzdaten für Immutep Limited Adr (IMMP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):